Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma

被引:22
|
作者
Abargel, A
Avinoach, I
Kravtsov, V
Boaz, M
Glezerman, M
Menczer, J [1 ]
机构
[1] Edith Wolfson Med Ctr, Dept Obstet & Gynecol, Gynecol Oncol Unit, Holon, Israel
[2] Edith Wolfson Med Ctr, Dept Pathol, Holon, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
endometrial carcinoma; endometrial carcinosarcoma; p27; expression; p53;
D O I
10.1111/j.1048-891x.2004.014221.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to assess both p27 and p53 expression in the stromal and epithelial component of carcinosarcoma and to assess if their expression in the latter is different than in endometrial carcinoma. Immunohistochemical staining for p27 and p53 was performed on paraffin-embedded tissue blocks of 18 uterine specimens with carcinosarcoma and their expression assessed. Their expression in the epithelial element was also compared to that in 35 paraffin-embedded tissue blocks of endometrial endometrioid carcinoma. Reduced p27 expression was observed in a similarly high proportion of the stromal (77.8%) as well as of the epithelial component (66.7%) of carcinosarcoma. Although statistically not significant, the proportion of reduced p27 expression in endometrial carcinoma (85.7%) was higher than in the epithelial element of carcinosarcoma. The percentage of p53 overexpression in both elements of carcinosarcomas and in endometrial carcinomas was low and also similar (27.8 and 20.0%, respectively). Our results indicate that reduced p27 expression is common and p53 overexpression is infrequent in carcinosarcoma. Their similar rates of expression in the stromal and epithelial elements of the tumor support the contention of a monoclonal origin of carcinosarcoma. Unexpectedly, reduced p27 expression is more common in endometrial carcinoma than in the epithelial element of carcinosarcoma, in spite of the less favorable prognosticators and outcome in the latter. Further studies of p27 expression in carcinosarcoma are indicated to establish its clinical value in this aggressive malignancy.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 50 条
  • [1] p53 and p27 gene expression in subserosal gallbladder carcinoma
    Roa E, Ivan
    Lantadilla H, Soledad
    Ibacache S, Gilda
    de Aretxabala U., Xabier
    REVISTA MEDICA DE CHILE, 2009, 137 (08) : 1017 - 1022
  • [2] Significantly decreased p27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression)
    Özkara, SK
    Corakci, A
    PATHOLOGY & ONCOLOGY RESEARCH, 2004, 10 (02) : 89 - 97
  • [3] Analysis of endometrial carcinoma with subclonal P53 expression
    Dashora, A.
    Thompson, E.
    Broek, J. V.
    Lum, A.
    Senz, J.
    Leung, S.
    VIRCHOWS ARCHIV, 2020, 477 : S61 - S61
  • [4] Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma
    Jing, Zhao
    Nan, Ke-Jun
    Hu, Mei-Long
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (13) : 1910 - 1916
  • [6] The role of p27 in endometrial carcinoma
    Nycum, LR
    Smith, LM
    Farley, JH
    Kost, ER
    Method, MW
    Birrer, MJ
    GYNECOLOGIC ONCOLOGY, 2001, 81 (02) : 242 - 246
  • [7] The clinical significance of p53, p21, and p27 expressions in rectal carcinoma
    Lebe, B
    Sarioglu, S
    Sökmen, S
    Ellidokuz, H
    Füzün, M
    Küpelioglu, A
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2005, 13 (01): : 38 - 44
  • [8] p53 expression in tissue adjacent to endometrial carcinoma
    Shem, EB
    Fintsi, Y
    Avinoach, I
    Glezerman, M
    Menczer, J
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (06) : 548 - 550
  • [9] Expression of p53 in imprint smears of endometrial carcinoma
    Konstantinos, Kosmas
    Marios, Stamoulas
    Anna, Marouga
    Nikolaos, Kavantzas
    Efstratios, Patsouris
    Paulina, Athanassiadou
    DIAGNOSTIC CYTOPATHOLOGY, 2014, 42 (05) : 416 - 422
  • [10] P53 expression in adenomyosis in endometrial carcinoma patients
    Taskin, M
    Lallas, TA
    Shevchuk, M
    Barber, HRK
    GYNECOLOGIC ONCOLOGY, 1996, 62 (02) : 241 - 246